A Phase 2/3 interventional study of Standard TME surgery and Long course concurrent chemoradiation with capecitabine and radiotherapy in Adenocarcinoma of the Rectum, sponsored by University of Birmingham. Active, not recruiting at 5 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by University of Birmingham · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 15th largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2017, is the only one in phase 2/3, reaches primary completion later than 12 of the 19 other live ones, and was the 30th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
KU Leuven · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
University Hospital, Antwerp · Sites in Belgium
Ages 18+
KU Leuven · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 19
First in 1993; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 380 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 156 across the 45 interventional studies, 188 across the 7 observational. Of the 34 that completed or were terminated, 5 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 56 have an industry lead sponsor. The 10 most frequent:
University of Birmingham is the lead sponsor of 182 studies on the registry; 28 are open to participants now.
University of Birmingham has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Rectal Neoplasms with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04503694Jules Bordet InstituteNeoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bowel cancer is the second most common tumour with 41 000 new cases diagnosed annually in the UK, 447 000 across Europe and 1.36 million worldwide; of which one third are located in the rectum. Standard primary radical Total Mesorectal Excision (TME) surgery is an oncologically effective treatment for early stage rectal cancer. However, resection of a low rectal tumour requires a permanent stoma in approximately 10% of cases while many more patients have a temporary stoma, some of which are not reversed. Radical surgery, which evolved to treat locally advanced, symptomatic tumours, may not be the optimal method of treatment for early screen-detected tumours and an organ preserving strategy may generate significantly less morbidity without substantially compromising oncological outcomes.
STAR-TREC is a rolling phase II/III study. Phase II aimed to assess the feasibility of a large, multi-centre randomised trial comparing radical surgery versus two contrasting organ saving treatments followed by selective transanal microsurgery. Phase III will evaluate two contrasting organ preservation strategies in terms of organ preservation rates, toxicity (clinician and patient-reported) and Health-Related Quality of Life (HRQoL).
The Phase II component of STAR-TREC (now completed) was a randomised, three arm (1:1:1) study using the following arms:
Organ saving treatments using:
Long course concurrent chemoradiation:
Short course radiotherapy:
The phase III component of STAR_TREC is now open and has a partially randomised patient preference design where patients choose between organ saving treatment or standard surgery.
Those who prefer organ preservation will undergo randomisation 1:1 between:
Those who prefer standard surgery or have no preference, will undergo standard TME surgery without neoadjuvant radiotherapy treatment.
For organ-preserving strategies in phase II and III, clinical response to radiotherapy determines the next treatment step. Radiotherapy response is evaluated using clinical exam, endoscopy and MRI. The first assessment at 11-13 weeks (from radiotherapy start) using composite clinical, endoscopic and MRI based assessment will identify a minority of non-responders who should convert to TME surgery. Patients demonstrating a satisfactory radiotherapy response at 11-13 weeks will be reassessed by endoscopy at 16-20 weeks. Re-evaluation at 16-20 weeks determines if the STAR-TREC criteria for complete response (CR) are met. Patients who achieve CR may progress directly to active surveillance. Those who do not fulfil the criteria for CR will progress to excision biopsy with transanal endoscopic microsurgery (TEM).
The phase II component of the study aimed to evaluate the feasibility of accelerating patient recruitment from 2 per month, as attained in the previous TREC study, to 6 per month internationally over a two-year period.
The STAR-TREC phase III study will evaluate whether a CRT or SCRT organ preservation strategy leads to higher organ preservation rates and should become first line treatment for early rectal cancer.
This objective can be divided into two main questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
MDT determines that all of the following treatment options are reasonable and feasible:
--TME surgery, (b) CRT (c) SCRT d) TEM.
For patients choosing organ preservation only:
If female and of , must:
Exclusion Criteria:
Unequivocal evidence of disease (includes resectable metastases)
-- Patients with equivocal radiological lesions (e.g. retroperitoneal, liver, lung) that are not classified as M1 are eligible if agreed by MDT
MRI node positive (≥N1, defined by protocol guidelines)
-- Patients with equivocal radiological findings that are either classified as NX or N0 are eligible
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radical total mesorectal excision
Procedure: Standard TME surgery
Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
Drug: Long course concurrent chemoradiation with capecitabine and radiotherapy
A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
Radiation: Short course radiotherapy
Total mesorectal excision
Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
Also known as: Xeloda is the brand name for capecitabine
A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
Phase II (Feasibility study) Primary Outcome: Recruitment Rate
Measured at 12 and 24 months. Target recruitment rates are ≥4 and ≥6 patients randomised per month at 12 and 24 months respectively for total accrual of 120 international cases. Each individual country will attempt to exceed the minimum recruitment required to sustain phase III (UK 75, the Netherlands 75, Denmark 30). If recruitment is on target in year two then consideration will be given to an early application for transition to phase III with a funding application and a formal protocol amendment.
Time frame: 24 Months
Phase III Primary Outcome: Organ Preservation
The primary endpoint of the STAR-TREC phase III study is the proportion of patients with successful organ preservation at 30 months from the start day of (chemo)radiotherapy treatment. This endpoint will be assessed for patients who prefer organ preservation and is defined as an in-situ rectum (includes patients subject to transanal local resection), no defunctioning stoma and an absence of active loco-regional cancer failure. The expected incidence of this outcome is approximately 60%.
Time frame: 30 Months from start day of (chemo)radiotherapy treatment.
Phase II (Feasibility study): Core Endpoint - Funding
Incidence of procurement of funding by one STAR-TREC international partner
Time frame: 12 Months
Phase II (Feasibility study): Core Endpoint - International Recruitment
Incidence of opening of STAR-TREC by one international partner
Time frame: 12 Months
Phase II (Feasibility study): Core Endpoint - Efficacy
Efficacy of organ preserving treatment arm on completion of phase II study: Is the organ saving rate more than 50% of patients with early stage rectal cancer at 12 months (following randomisation) achieved in the experimental arms? \[Name of Measurement: Rate of organ saving \>50% at 12 months; Unit of Measurement: no record of radical surgery at 12 months\]
Time frame: 12 Months
Phase II: Safety- Accuracy of MRI in predicting STAR-TREC eligibility
MRI \- Accuracy of MRI in predicting STAR-TREC eligibility (We will report the accuracy of MRI based patient selection according to each national standard, compared to the reference standard of post-operative histological staging. STAR-TREC will help develop international consensus in MRI reporting of mesorectal lymph node involvement by rectal cancer)
Time frame: 24 Months
Phase II: Safety - 30 day Mortality
\- Mortality
Time frame: 30 days
Phase II: Safety - 6 month Mortality
\- Mortality
Time frame: 6 Months
Phase II: Safety - Surgical Morbidity
\- Surgical morbidity
Time frame: 36 Months
Phase II: Safety - Tumour Recurrence/ Regrowth within Bowel Wall
\- Rate of tumour recurrence or regrowth within the bowel wall (experimental arm)
Time frame: 36 Months
Phase II: Safety - Tumour Recurrence within Mesorectum
\- Rate of tumour recurrence within the mesorectum (experimental arm)
Time frame: 36 Months
Phase II: Safety - Distant Metastasis
\- Rate of distant metastases
Time frame: 36 Months
Phase II: Safety - Pelvic Failure
\- Pelvic failure rate: expressed as a sum of the following (i) unresectable pelvic tumour, (ii) cases requiring beyond TME surgery or (iii) tumour recurrence or regrowth ≤1mm from the circumferential surgical margin after TME surgery.
Time frame: 36 Months
Phase II: Safety - Bowel
Bowel dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 36 Months
Phase II: Safety - Bladder
Bladder dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 36 Months
Phase II: Safety - Sexual dysfunction
Sexual dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 36 Months
Phase II: Efficacy - Stoma
Additional outcome measures pertinent to the phase III study examining the efficacy of organ saving versus standard surgery will also be collected: \- Proportion of patients with/ without a stoma at 30 days and one year
Time frame: 24 Months
Phase II: Efficacy - Tumour Down-staging
\- Histopathological assessment of tumour down-staging following radiotherapy according to depth of tumour invasion and the incidence of other high-risk features in comparison to non-irradiated (control) group
Time frame: 4.5 Months
Phase II: Efficacy - Active Monitoring
\- Proportion of patients identified by clinical and MRI assessment as suitable for active monitoring
Time frame: 4.5 Months
Phase II: Efficacy - Conversion Rate
\- Conversion rates from organ saving to radical surgery
Time frame: 36 Months
Phase II: Efficacy - Disease Survival
\- Disease free survival
Time frame: 36 Months
Phase II: Efficacy - Health-related Quality of Life score
Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 3 months
Phase II: Efficacy - Health-related Quality of Life score
Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 12 Months
Phase II: Efficacy - Health-related Quality of Life score
Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 24 Months
Phase II: Efficacy - Health-related Quality of Life score
Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.
Time frame: 36 Months
Phase II: Efficacy - Overall Survival
\- Overall survival
Time frame: 36 Months
Phase III: For the randomised comparison between organ-preserving strategies
Clinician-reported acute treatment related toxicity up to 30 days following completion of (chemo)radiotherapy
Time frame: 30 days from start day of (chemo)radiotherapy treatment.
Phase III: Complete Response *For the randomised comparison between organ-preserving strategies
Proportion of patients with Complete Response to (chemo)radiation therapy
Time frame: 30 months
Phase III: For the randomised comparison between organ-preserving strategies - Local Excision
Proportion of patients undergoing transanal local excision
Time frame: 20 weeks
Phase III: For the randomised comparison between organ-preserving strategies - Organ Loss
Time to event of organ loss assessed for patients who prefer organ preservation
Time frame: Defined as the length of time from the start date of trial treatment until TME surgery
Phase III: For the randomised comparison between organ-preserving strategies - Non-Regrowth
Non-regrowth pelvic tumour control to 36 months; defined as the length of time from the start date of trial treatment until death (any cause) or development of unequivocal pelvic recurrence but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery
Time frame: 36 months
Phase III: For the randomised comparison between organ-preserving strategies - Metastasis Free Survival
Metastasis free survival to 36 months; defined as the length of time from the start date of trial treatment until death (any cause) or detection of distant metastasis
Time frame: 36 months
Phase III: For the randomised comparison between organ-preserving strategies - Non-regrowth Disease Free Survival
Non-regrowth -disease free survival to 36 months; defined as the length of time from the start of trial treatment until death (any cause), detection of local pelvic recurrence or distant metastasis but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery
Time frame: 36 months
Phase III: For the randomised comparison between organ-preserving strategies - Overall Survival
Overall survival to 60 months defined as the length of time from the start date of trial treatment until death (any cause)
Time frame: 60 months
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Toxicity
Clinician-reported acute treatment related toxicity up to 30 days following completion of (chemo)radiotherapy or date of initial surgery
Time frame: 30 days
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Non-regrowth Pelvic Tumour Control
Non-regrowth pelvic tumour control to 36 months; defined as the length of time from the start date of (chemo)radiotherapy or date of initial surgery until death (any cause) or development of unequivocal pelvic recurrence but not including patients who preferred organ preservation and developed local regrowth which was resected with clear margins using standard TME surgery
Time frame: 36 months
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Metastasis Free Survival
Metastasis-free survival to 36 months; defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause) or detection of distant metastasis
Time frame: 36 months
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Disease-free Survival
Disease-free survival to 36 months; defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause), detection of local pelvic recurrence or distant metastasis but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery
Time frame: 36 months
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Overall Survival
Overall survival to 60 months defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause))
Time frame: 60 months
Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret
Decision regret at 24 months measured using the validated Decision regret scale questionnaire. The Decision Regret Scale is a 5-item Likert-type measure written to assess regret or remorse following a medical decision that takes less than 5 minutes to complete. High scores suggest high regret over a health care decision. Scores may be transformed to a scale of 0 (no regret) to 100 (high regret).
Time frame: 24 months
Plan to share: No
Started Jun 2017 (actual). Primary completion is estimated for Aug 2027, 122 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.